MA33060B1 - Formulations galéniques de composés organiques - Google Patents
Formulations galéniques de composés organiquesInfo
- Publication number
- MA33060B1 MA33060B1 MA34114A MA34114A MA33060B1 MA 33060 B1 MA33060 B1 MA 33060B1 MA 34114 A MA34114 A MA 34114A MA 34114 A MA34114 A MA 34114A MA 33060 B1 MA33060 B1 MA 33060B1
- Authority
- MA
- Morocco
- Prior art keywords
- tablet
- central portion
- pharmacy
- capsules
- organic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une forme de dosage unitaire solide pour administration orale sous la forme d'un comprimé, doté d'une partie centrale et d'un enrobage externe. Ladite partie centrale dudit comprimé comprend une quantité thérapeutiquement efficace d'Aliskiren, ou un sel pharmaceutiquement acceptable de celui-ci, et l'enrobage externe se présente sous la forme d'un revêtement de film qui possède des propriétés de masquage de goût et/ou une fonctionnalité de libération contrôlée. De préférence, le comprimé avec partie centrale fait partie d'un système multiparticulaire, et est en particulier un mini-comprimé. La forme de dosage oral solide est particulièrement adaptée à un usage pédiatrique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09151496 | 2009-01-28 | ||
PCT/EP2010/050886 WO2010086312A1 (fr) | 2009-01-28 | 2010-01-27 | Formulations galéniques de composés organiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33060B1 true MA33060B1 (fr) | 2012-02-01 |
Family
ID=40770648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34114A MA33060B1 (fr) | 2009-01-28 | 2010-01-27 | Formulations galéniques de composés organiques |
Country Status (28)
Country | Link |
---|---|
US (1) | US20110287100A1 (fr) |
EP (1) | EP2391345B1 (fr) |
JP (1) | JP2012516299A (fr) |
KR (1) | KR20110117199A (fr) |
CN (1) | CN102300558A (fr) |
AR (1) | AR075179A1 (fr) |
AU (1) | AU2010209787B2 (fr) |
BR (1) | BRPI1007452A2 (fr) |
CA (1) | CA2749531A1 (fr) |
CL (1) | CL2011001817A1 (fr) |
CO (1) | CO6400184A2 (fr) |
EC (1) | ECSP11011289A (fr) |
ES (1) | ES2525648T3 (fr) |
HK (1) | HK1161125A1 (fr) |
IL (1) | IL213918A0 (fr) |
MA (1) | MA33060B1 (fr) |
MX (1) | MX2011007779A (fr) |
MY (1) | MY153852A (fr) |
NZ (1) | NZ593622A (fr) |
PE (1) | PE20110943A1 (fr) |
PL (1) | PL2391345T3 (fr) |
PT (1) | PT2391345E (fr) |
RU (1) | RU2535090C2 (fr) |
SG (1) | SG172226A1 (fr) |
TN (1) | TN2011000307A1 (fr) |
TW (1) | TWI468191B (fr) |
WO (1) | WO2010086312A1 (fr) |
ZA (1) | ZA201104489B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5822758B2 (ja) * | 2011-03-02 | 2015-11-24 | 第一三共ヘルスケア株式会社 | 速溶性防湿フィルムコーティング製剤及びその製造方法 |
EP2596802A1 (fr) * | 2011-11-23 | 2013-05-29 | PLS-Design GmbH | Composition pharmaceutique pour le traitement des réactions allergiques |
AU2017215530B2 (en) * | 2016-02-03 | 2019-09-12 | Novartis Ag | Galenic formulations of organic compounds |
US20210308054A1 (en) * | 2018-08-10 | 2021-10-07 | Kissei Pharmaceutical Co., Ltd. | Sucroferric oxyhydroxide-containing granules and pharmaceutical composition |
SG11202108690YA (en) | 2019-02-22 | 2021-09-29 | Catalent Uk Swindon Zydis Ltd | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen |
EP3927313A1 (fr) * | 2019-02-22 | 2021-12-29 | Catalent U.K. Swindon Zydis Limited | Préservation de particules d'api à revêtement fonctionnel produites par des procédés de mélange sans solvant dans une suspension aqueuse |
WO2021011538A1 (fr) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
DE19842753A1 (de) * | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AR034813A1 (es) * | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
WO2004100871A2 (fr) * | 2003-05-09 | 2004-11-25 | Pharmacia Corporation | Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine |
MY144477A (en) | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
WO2005105054A1 (fr) * | 2004-04-15 | 2005-11-10 | Dr. Reddy's Laboratories Ltd. | Forme de dosage ayant une stabilité polymorphique |
US20080085914A1 (en) * | 2004-10-08 | 2008-04-10 | David Louis Feldman | Use Of Organic Compounds |
ES2364538T3 (es) * | 2007-09-28 | 2011-09-06 | Novartis Ag | Combinación farmacéutica de alisquireno y valsartán. |
-
2010
- 2010-01-27 PT PT107020927T patent/PT2391345E/pt unknown
- 2010-01-27 US US13/145,454 patent/US20110287100A1/en not_active Abandoned
- 2010-01-27 WO PCT/EP2010/050886 patent/WO2010086312A1/fr active Application Filing
- 2010-01-27 RU RU2011135417/15A patent/RU2535090C2/ru not_active IP Right Cessation
- 2010-01-27 SG SG2011044450A patent/SG172226A1/en unknown
- 2010-01-27 AR ARP100100193A patent/AR075179A1/es unknown
- 2010-01-27 ES ES10702092.7T patent/ES2525648T3/es active Active
- 2010-01-27 KR KR1020117019809A patent/KR20110117199A/ko not_active Application Discontinuation
- 2010-01-27 MY MYPI2011003186A patent/MY153852A/en unknown
- 2010-01-27 PL PL10702092T patent/PL2391345T3/pl unknown
- 2010-01-27 JP JP2011546822A patent/JP2012516299A/ja active Pending
- 2010-01-27 CA CA2749531A patent/CA2749531A1/fr not_active Abandoned
- 2010-01-27 MX MX2011007779A patent/MX2011007779A/es not_active Application Discontinuation
- 2010-01-27 AU AU2010209787A patent/AU2010209787B2/en not_active Ceased
- 2010-01-27 NZ NZ593622A patent/NZ593622A/en not_active IP Right Cessation
- 2010-01-27 CN CN2010800057033A patent/CN102300558A/zh active Pending
- 2010-01-27 TW TW99102290A patent/TWI468191B/zh not_active IP Right Cessation
- 2010-01-27 MA MA34114A patent/MA33060B1/fr unknown
- 2010-01-27 EP EP10702092.7A patent/EP2391345B1/fr not_active Not-in-force
- 2010-01-27 BR BRPI1007452A patent/BRPI1007452A2/pt not_active IP Right Cessation
- 2010-01-27 PE PE2011001391A patent/PE20110943A1/es not_active Application Discontinuation
-
2011
- 2011-06-16 TN TN2011000307A patent/TN2011000307A1/fr unknown
- 2011-06-17 ZA ZA2011/04489A patent/ZA201104489B/en unknown
- 2011-07-04 IL IL213918A patent/IL213918A0/en unknown
- 2011-07-27 CL CL2011001817A patent/CL2011001817A1/es unknown
- 2011-07-28 CO CO11095153A patent/CO6400184A2/es not_active Application Discontinuation
- 2011-08-26 EC EC2011011289A patent/ECSP11011289A/es unknown
-
2012
- 2012-02-27 HK HK12101945.0A patent/HK1161125A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MY153852A (en) | 2015-03-31 |
AU2010209787A1 (en) | 2011-07-14 |
JP2012516299A (ja) | 2012-07-19 |
RU2535090C2 (ru) | 2014-12-10 |
PE20110943A1 (es) | 2012-01-22 |
BRPI1007452A2 (pt) | 2016-02-16 |
US20110287100A1 (en) | 2011-11-24 |
KR20110117199A (ko) | 2011-10-26 |
TN2011000307A1 (en) | 2012-12-17 |
ZA201104489B (en) | 2012-02-29 |
CO6400184A2 (es) | 2012-03-15 |
ECSP11011289A (es) | 2011-09-30 |
CN102300558A (zh) | 2011-12-28 |
CA2749531A1 (fr) | 2010-08-05 |
WO2010086312A1 (fr) | 2010-08-05 |
AU2010209787B2 (en) | 2013-06-06 |
EP2391345A1 (fr) | 2011-12-07 |
TWI468191B (zh) | 2015-01-11 |
IL213918A0 (en) | 2011-07-31 |
RU2011135417A (ru) | 2013-03-10 |
SG172226A1 (en) | 2011-07-28 |
AR075179A1 (es) | 2011-03-16 |
CL2011001817A1 (es) | 2012-01-13 |
HK1161125A1 (en) | 2012-08-24 |
ES2525648T3 (es) | 2014-12-26 |
MX2011007779A (es) | 2011-08-12 |
PT2391345E (pt) | 2014-12-03 |
TW201038300A (en) | 2010-11-01 |
NZ593622A (en) | 2013-12-20 |
EP2391345B1 (fr) | 2014-09-03 |
PL2391345T3 (pl) | 2015-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33060B1 (fr) | Formulations galéniques de composés organiques | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
EP2248519A3 (fr) | Formes galéniques de film non mucoadhésifs | |
MA38146A1 (fr) | Nouveaux dérivés du benzimidazole comme antagonistes ep4 | |
MA31396B1 (fr) | Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes | |
MY145439A (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MY156822A (en) | Indole derivatives as s1p1 receptor agonists | |
SG151336A1 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
CY1110824T1 (el) | Διασπεipoμενη στο στομα φαρμακευτικη συνθεση για απο του στοματος, μεσω του στοματικου βλεννογονου ή υπογλωσσια χορηγηση αγομελατινης | |
TNSN06440A1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
WO2007095091A3 (fr) | Administration orale d'agents thérapeutiques utilisant des agonistes à jonctions serrées | |
MA30466B1 (fr) | Nouvelle forme d'administration du racecadotril | |
TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
MA31706B1 (fr) | Formulations galéniques de composés organiques | |
TW200600098A (en) | Solid orally ingestible formulations of tetrodotoxin | |
MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
BRPI0817275A2 (pt) | Combinação farmacêutica de alisquireno e valsartana | |
CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. | |
MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
WO2008151811A3 (fr) | Procédé de fabrication d'un médicament contenant du trihydrate d'hydrochlorure de vardénafil | |
TR200102811T2 (tr) | Oral uygulama için, tolpersiyon içeren farmasötik preparat. | |
WO2007007182A3 (fr) | Formes galeniques solides d'agent antiepileptique |